- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07941089
Added Value of HR-pQCT in Detecting Calcium Deposits in Rheumatoid Arthritis (HAND-QCT-RA)
Added Value of HR-pQCT: Detecting and Characterizing Calcium Deposits Suggestive of CPPD in the Hand and Wrist of Rheumatoid Arthritis Patients (HAND-QCT-RA)
The goal of this clinical trial is to learn if a high-resolution computed tomography scan (HR-pQCT) can detect and describe calcium crystal deposits in the hands and wrists of adults with rheumatoid arthritis (RA). The main questions it aims to answer are:
- How often does the HR-pQCT scan detect calcium crystal deposits in the hand and wrist joints of people with RA?
- Can the HR-pQCT scan find calcium deposits that standard tests (x-rays and ultrasound) miss? Researchers will compare scan results from participants with RA to results from participants with known calcium pyrophosphate deposition (CPPD) and participants without joint inflammation.
During a single clinic visit, participants will:
- Have standard x-rays of their hands and wrists
- Have a routine ultrasound of their hands and wrists
- Have an HR-pQCT scan of their wrist and finger joints, which takes about 15 to 20 minutes and uses a very low dose of radiation
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Calcium pyrophosphate deposition (CPPD) disease is an underdiagnosed crystal arthritis that frequently mimics rheumatoid arthritis (RA) or coexists with it, particularly when presenting as chronic inflammatory polyarthritis involving the wrists and metacarpophalangeal (MCP) joints. Although synovial fluid crystal identification remains the reference standard, aspiration of small hand joints is often technically unfeasible or non-diagnostic. Consequently, diagnosis relies heavily on conventional radiography and musculoskeletal ultrasonography, both of which suffer from recognized limitations in detecting subtle or early calcifications.
High-resolution peripheral quantitative computed tomography (HR-pQCT) provides superior spatial resolution and volumetric bone microarchitecture assessment. This multicenter, cross-sectional pilot study investigates whether HR-pQCT can enhance the detection and structural characterization of CPPD-suggestive calcium deposits within the triangular fibrocartilage complex (TFCC) and 2nd/3rd MCP hyaline cartilage.
To enable combined multi-site analysis, cross-calibration between the two participating tertiary centers (IRCCS Istituto Ortopedico Rizzoli, utilizing a second-generation Scanco XtremeCT II system, and AOUI Verona, utilizing a RAR Medical Devices ArtiCAT cone-beam system) is conducted using the European Forearm Phantom (EFP; QRM AG). Scans follow harmonized volumetric acquisition protocols based on international recommendations (SPECTRA group). All imaging acquisitions (radiographs, ultrasound, and HR-pQCT) are evaluated independently and in a double-blinded manner by trained musculoskeletal radiologists and rheumatologists.
At the patient level, a participant is classified as positive if at least one calcium deposit is detected in any of the examined joints. Because each participant undergoes imaging across multiple anatomical sites (the TFCC of the wrist and the 2nd and 3rd metacarpophalangeal joints of both hands), observations from the same individual are correlated. To account for this within-subject correlation without losing anatomical detail, site-specific analyses will be conducted using mixed-effects models or generalized estimating equations (GEE).
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Jacopo Ciaffi
- Telefoonnummer: +39 051.6445505
- E-mail: jacopo.ciaffi@ior.it
Studie Locaties
-
-
Bologna
-
Bologna, Bologna, Italië, 40136
- IRCCS Istituto Ortopedico Rizzoli - SSD Medicina e Reumatologia
-
-
Verona
-
Verona, Verona, Italië, 37134
- Azienda Ospedaliera Universitaria Integrata di Verona - UO di Reumatologia
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Rheumatoid Arthritis (RA) Cohort:
- Age ≥ 60 years
- Diagnosis of Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria
- Clinical diagnosis confirmed by an expert rheumatologist
- Current or past inflammatory involvement of the hand and/or wrist
- Written informed consent obtained
Calcium Pyrophosphate Deposition (CPPD) Cohort:
- Age ≥ 60 years
- Established diagnosis of CPPD based on synovial fluid crystal analysis and/or imaging findings compatible with current classification criteria
- Current or past inflammatory involvement of the hand and/or wrist
- Written informed consent obtained
Control Cohort (Non-inflammatory Controls):
- Age ≥ 60 years
- Outpatient evaluation at one of the participating centers for a condition not suggestive of CPPD, rheumatoid arthritis, erosive osteoarthritis, or other inflammatory joint diseases
- Clinical indication for conventional radiography of the hand and/or wrist as part of routine clinical practice
- Absence of past or present hand or wrist joint swelling suggestive of inflammatory arthritis
- Written informed consent obtained
Exclusion Criteria:
All Cohorts:
- Contraindications to CT-based imaging (including the inability to immobilize the hand and wrist during image acquisition)
- Known causes of secondary CPPD (e.g., hyperparathyroidism, hemochromatosis, hypomagnesemia, hypophosphatasia)
- Presence of hand/wrist prosthesis or osteosynthesis material interfering with image acquisition
- Inability to provide written informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Rheumatoid Arthritis (RA) Cohort
Patients with RA and current or prior hand/wrist involvement (n = 60). |
High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.
Andere namen:
|
|
Actieve vergelijker: Healthy / Non-inflammatory Controls
Subjects undergoing hand/wrist imaging for non-inflammatory conditions (n = 60). |
High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.
Andere namen:
|
|
Actieve vergelijker: CPPD Positive Control Cohort
Patients with proven CPPD disease (n = 20). |
High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in rheumatoid arthritis
Tijdsspanne: Baseline (single imaging visit)
|
Percentage of participants with rheumatoid arthritis with at least one calcium deposit suggestive of CPPD detected by HR-pQCT at the triangular fibrocartilage complex (TFCC) and/or the 2nd-3rd metacarpophalangeal (MCP) joints. |
Baseline (single imaging visit)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of HR-pQCT-positive cases missed by conventional imaging
Tijdsspanne: Baseline (single imaging visit)
|
Percentage of participants with no CPPD-suggestive calcium deposits on either conventional radiography or ultrasonography who have at least one CPPD-suggestive calcium deposit on HR-pQCT. |
Baseline (single imaging visit)
|
|
Agreement between conventional radiography and HR-pQCT for CPPD-suggestive calcium deposits
Tijdsspanne: Baseline (single imaging visit)
|
Cohen's kappa coefficient for agreement between conventional radiography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits. |
Baseline (single imaging visit)
|
|
Agreement between ultrasonography and HR-pQCT for CPPD-suggestive calcium deposits
Tijdsspanne: Baseline (single imaging visit)
|
Cohen's kappa coefficient for agreement between ultrasonography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits. |
Baseline (single imaging visit)
|
|
Agreement between combined conventional imaging and HR-pQCT for CPPD-suggestive calcium deposits
Tijdsspanne: Baseline (single imaging visit)
|
Cohen's kappa coefficient for agreement between combined conventional imaging and HR-pQCT. A participant is classified as positive on combined conventional imaging if deposits are detected on radiography, ultrasonography, or both. |
Baseline (single imaging visit)
|
|
Volume of CPPD-suggestive calcium deposits on HR-pQCT
Tijdsspanne: Baseline (single imaging visit)
|
Total volume of CPPD-suggestive calcium deposits per participant, measured on HR-pQCT (mm³), in participants with at least one deposit. |
Baseline (single imaging visit)
|
|
Volumetric density of CPPD-suggestive calcium deposits on HR-pQCT
Tijdsspanne: Baseline (single imaging visit)
|
Mean volumetric density of CPPD-suggestive calcium deposits (mg HA/cm³), measured on HR-pQCT, in participants with at least one deposit. |
Baseline (single imaging visit)
|
|
Anatomical distribution of CPPD-suggestive calcium deposits on HR-pQCT
Tijdsspanne: Baseline (single imaging visit)
|
Percentage of participants with deposits at the TFCC only, at the 2nd-3rd MCP joints only, or at both sites, among participants with at least one deposit on HR-pQCT. |
Baseline (single imaging visit)
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in seronegative vs seropositive rheumatoid arthritis
Tijdsspanne: Baseline (single imaging visit)
|
Percentage of participants with at least one CPPD-suggestive calcium deposit on HR-pQCT, reported separately for seronegative participants (RF- and ACPA-negative) and seropositive participants. |
Baseline (single imaging visit)
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Filippou G, Adinolfi A, Cimmino MA, Scire CA, Carta S, Lorenzini S, Santoro P, Sconfienza LM, Bertoldi I, Picerno V, Di Sabatino V, Ferrata P, Galeazzi M, Frediani B. Diagnostic accuracy of ultrasound, conventional radiography and synovial fluid analysis in the diagnosis of calcium pyrophosphate dihydrate crystal deposition disease. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):254-60. Epub 2016 Feb 9.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-8. doi: 10.1136/ard.2010.138461.
- Krekeler M, Baraliakos X, Tsiami S, Braun J. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022 Jun;8(2):e002383. doi: 10.1136/rmdopen-2022-002383.
- Tedeschi SK, Becce F, Pascart T, Guermazi A, Budzik JF, Dalbeth N, Filippou G, Iagnocco A, Kohler MJ, Laredo JD, Smith SE, Simeone FJ, Yinh J, Choi H, Abhishek A. Imaging Features of Calcium Pyrophosphate Deposition Disease: Consensus Definitions From an International Multidisciplinary Working Group. Arthritis Care Res (Hoboken). 2023 Apr;75(4):825-834. doi: 10.1002/acr.24898. Epub 2022 Nov 23.
- Barnabe C, Feehan L; SPECTRA (Study GrouP for XTrEme-CT in RA). High-resolution peripheral quantitative computed tomography imaging protocol for metacarpophalangeal joints in inflammatory arthritis: the SPECTRA collaboration. J Rheumatol. 2012 Jul;39(7):1494-5. doi: 10.3899/jrheum.120218. No abstract available.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Kristalartropathieën
- Musculoskeletale aandoeningen
- Artritis
- Gewrichtsziekten
- Reumatische aandoeningen
- Metabole ziekten
- Bindweefselziekten
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Calciummetabolismestoornissen
- Voedings- en stofwisselingsziekten
- Huid- en bindweefselaandoeningen
- Artritis, reumatoïde
- Calcinose
- Chondrocalcinose
Andere studie-ID-nummers
- HAND-QCT-RA
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .